賽諾菲料仿製藥競爭加劇 今年盈利將大幅放緩
賽諾菲(Sanofi)第四季經調整後每股盈利爲1.71歐元,不及市場預期的1.72歐元。公司稱,隨着多發性硬化症藥物Aubagio的仿製藥競爭加劇,預計今年盈利增長將放緩,按固定匯率計算核心每股盈利或只有低單位數增長,遠不及去年的雙位數增幅。
Aubagio今年春季將在美國面臨仿製藥的競爭,雖然治療哮喘及皮膚病的藥物Dupixent繼續推動賽諾菲的增長,但公司今年將需要爲新藥品增加營銷開支。公司預計,今年Dupixent的銷售額可能會超過100億歐元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.